KORU Medical Systems Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
FY Revenue (est.)
$48.7Mnext fiscal year
FY EPS (est.)
$0.02next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Net Revenues Quarterly11.8MTarget: 47500000 - 50000000
Gross Margin Quarterly61.5%Target: 61 - 63%
Adjusted EBITDA Quarterly-10KTarget: Positive
Cash Usage / Generation Quarterly-100KTarget: Positive Cash Flow
Watch Items
- Regulatory clearance of the 510(k) application for the Freedom Infusion System with DeferoxamineTrigger: FDA clearance decisionAction: Assess commercial launch timeline and addressable market penetration of 200,000 annual infusions.
- Pharma Services and Clinical Trials (PST) pipeline progressionTrigger: Phase III clinical trial milestones for two non-Ig collaborationsAction: Evaluate long-term commercialization potential and recurring revenue streams from non-Ig drug opportunities.
- Gross margin compression from tariff-related charges and production costsTrigger: Gross margin falling below 61.0%Action: Review cost-saving initiatives, pricing adjustments, and geographic sales mix optimization.
Research as of 20 Jun 2026